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Abstract
Objectives—Tenofovir disoproxil fumarate (TDF) has been associated with renal insufficiency.
Co-administration with boosted protease inhibitors (PIs), which increases its exposure, may
further increase the risk of renal insufficiency.
Methods—We compared the incidence of renal events among women taking TDF co-
administered with lopinavir/ritonavir (LPV/r) versus those co-administering TDF with nevirapine
(NVP). Renal events were defined as a confirmed drop in creatinine clearance associated with a
serum creatinine grade 2 or higher, or that leading to treatment modification.
Results—Overall, 741 HIV-infected women were enrolled into the study. Of these, 24 (3.2%)
had reportable renal events (18 in LPV/r arm, 6 in NVP arm). In multivariate analysis, renal events
were significantly associated with the LPV/r arm (odds ratio [OR]=3.12, 95% confidence interval
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[CI] 1.21, 8.05]; p=0.019), baseline HIV-1 RNA (OR=2.65, 95% CI: 1.23, 5.69 per 1 log10
copies/mL higher; p=0.013) and baseline creatinine clearance (OR=0.83, 95% CI 0.70–0.98 per 10
mL/min higher; p=0.030). In multivariate analysis evaluating renal events requiring treatment
modification, only baseline HIV-1 RNA and creatinine clearance were significantly associated
(OR=4.41, 95% CI 1.65, 11.78 per 1 log10 copies/mL higher; p= 0.003 and OR=0.80, 95% CI
0.64, 0.99 per 10 mL/min higher; p= 0.040, respectively).
Conclusion—The rates of renal events were relatively low in the two treatment arms. However,
patients taking TDF co-administered with LPV/r had significantly more renal events compared to
those co-administered with NVP. Furthermore, higher baseline HIV RNA and lower creatinine
clearance were associated with the development of renal insufficiency requiring treatment
modification.
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INTRODUCTION
HIV/AIDS remains an important medical challenge globally, especially in sub-Saharan
Africa. The roll-out of combination antiretroviral therapy (cART) across the region has led
to significant reduction in AIDS mortality [1]. While a cART treatment gap exists with
respect to those in need of therapy, the long term safety issues of those on treatment are
moving to the forefront. The most recent WHO guidelines [2] recommend that ART
programs shift away from stavudine (d4T) based therapy toward tenofovir (TDF) or
zidovudine (AZT) based first line cART due to such safety concerns.
As TDF use becomes more widespread, one safety concern is the potential for renal toxicity.
Depending on program guidelines, TDF may be a component of either first line non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy, or second line protease
inhibitor (PI)-based therapy. The renal safety profile in each scenario may differ; this issue
has particular importance for programs with limited safety monitoring. Although the clinical
significance of this renal toxicity remains controversial [3–5], the need for continued
vigilance cannot be overemphasized. When TDF is co-administered with ritonavir(r)
boosted PIs, TDF exposure rises by about 20–30% [6–7], although it is unclear if this
change in TDF exposure increases the risk of nephrotoxicity. Estimated glomerular filtration
rate declined significantly more among patients who took TDF with boosted PIs compared
with those taking TDF with NNRTI agents [8–9]. However, other studies have failed to
demonstrate such incident renal insufficiency in association with the use of TDF co-
administered with boosted PIs [3, 10–11].
The ACTG A5208 clinical trial randomized HIV-infected women to receive tenofovir/
emtricitabine (TDF/FTC) plus nevirapine (NVP) or TDF/FTC plus lopinavir/ritonavir
(LPV/r) with a goal of determining the impact of previous single dose NVP exposure on
virologic response [12–13]. Using data from this randomized trial, we evaluated the
incidence of renal events and examined if co-administration of LPV/r with TDF as a risk
factor for TDF treatment discontinuation.
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This analysis is derived from the A5208 study, “Optimal Combination Therapy After
Nevirapine Exposure (OCTANE)”. Participants were cART-naive HIV-infected women
aged ≥13 years with a CD4 count of < 200 cells/mm3 enrolled at sites in eastern and
southern Africa. For entry, all had creatinine clearance (CrCl) of at least ≥60 mL/min,
calculated using the Cockcroft-Gault formula [14, 15], and a Karnofsky score of ≥70.
STUDY PROTOCOL
The OCTANE trial has previously been described [12–13]. Briefly, OCTANE study was a
phase III study comprising two randomized controlled trials running concurrently. One trial
enrolled women who reported prior exposure to single dose nevirapine (sdNVP) for
prevention of mother-to-trial transmission of HIV, and the other trial enrolled women who
reported no prior sdNVP exposure. Both trials compared the virological response to NNRTI-
based versus PI-based ART. Participants were randomized to start cART with either NVP
and FTC/TDF or LPV/r and FTC/TDF. Participants who discontinued NVP or LPV/r, either
because of virologic failure, toxicity, or intolerability, could be switched to LPV/r or NVP,
respectively.
Following randomization, study participants were seen at weeks 2, 4, 8, 12, 16, 24, and
every 12 weeks thereafter until the last woman randomized reached 48 weeks. Chemistry
tests, including serum creatinine, were performed at weeks 4, 12, 24, and then every 12
weeks. Chemistry laboratory results that were Grade 2 or higher per the Division of AIDS
(DAIDS) toxicity table [16], or those resulting in treatment change were reported to the
database. Per protocol, any calculated CrCl less than 50mL/min required repeat testing
within 1 week. For confirmed levels less than 50mL/min, all cART was held or TDF was
replaced with an appropriately renal-dose-adjusted NRTI alternative while investigations for
alternative etiologies for renal insufficiency were explored. TDF was permanently
discontinued if no other potential cause was determined. Those with alternative etiologies of
their renal insufficiency could be rechallenged with TDF once CrCl was greater than or
equal to 60 mL/min, but if CrCl decreased after rechallenge, TDF was permanently replaced
with another NRTI agent.
IDENTIFICATION OF RENAL EVENTS
The primary outcome for this analysis was the development of a renal event, defined as a
drop in creatinine clearance associated with a serum creatinine value of Grade 2 or greater
(>1.4 times the upper limit of normal), as well as any renal events, including confirmed
calculated CrCl less than 50 mL/min, which led to interruption or discontinuation of TDF.
The secondary outcome for this analysis included only those renal events leading to
temporary or permanent discontinuation of TDF.
To identify potential renal events for inclusion in the analysis, the adverse event database for
the OCTANE study was screened for adverse events related to serum creatinine levels, CrCl,
or renal diagnoses. This included a search of adverse event records in which the term
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“RENAL” was used in the MedDRA [17] preferred or lower level terms for the events. In
addition, we reviewed causes of death for potential additional events and the cART records
for reasons for changes in cART regimens. Adverse events that were identified by this
search had no associated serum creatinine or CrCl results, or had serum creatinine of Grade
1 or lower and CrCl greater than 50mL/min, and which did not lead to any change in cART
were excluded from the analysis. Renal events that were pre-existing prior to the start of
study treatment were also excluded from the analysis.
DATA ANALYSIS
The log rank test was used to compare randomized arms with respect to time to a renal
event. Exact logistic regression was used to identify factors associated with increased risk of
a renal event. In multivariate modeling, stepwise variable selection was used initially to
identify factors predictive of increased odds of a renal event with a p-value of less than 0.05
when added to a model which included variables for randomized treatment and prior
exposure to sdNVP. Age was also included as a potential confounder of creatinine clearance.
RESULTS
Overall, 741 HIV infected women were enrolled in the OCTANE study, including 241
women (33%) with prior sdNVP exposure. Baseline characteristics were comparable
between the two randomized treatment arms with a mean creatinine and CrCl of 0.71 mg/dL
and 112 mL/min, respectively (Table 1). The median duration of follow-up was 2.3 years
(10th, 90th percentiles: 1.2, 3.1 years).
Twenty-four women experienced renal events, including 18 (4.9%) in the LPV/r arm and 6
(1.6%) in the NVP arm. All 24 women were receiving TDF and all except one were
receiving their randomized regimen at the time of the event (i.e. LPV/r or NVP; one woman
randomized to LPV/r was receiving efavirenz because of concomitant tuberculosis
treatment). Eighteen of the 24 women had moderate (Grade 2) or higher elevated serum
creatinine values (14 [3.8%] among women randomized to LPV/r and 4 [1.1%] among
women randomized to NVP), including 12 with severe (Grade 3) or higher values (9 [2.4%]
for the LPV/r arm and 3 [0.8%] for the NVP arm). Figure 1A shows the cumulative
incidence over time of renal events. Events primarily occurred early after starting treatment,
with a decreasing rate over time. The rate of renal events was significantly higher in the
LPV/r arm compared to the NVP arm (p=0.014).
Twenty-two of the 24 women had CrCl <50 mL/min; both women with higher CrCl had
moderately elevated serum creatinine values (both were receiving LPV/r). Sixteen of the 22
also met criteria for temporary (2 women) or permanent discontinuation (14 women) of
TDF, including 11 [3.0%] among women randomized to LPV/r and 5 [1.4%] among women
randomized to NVP. The 2 women who discontinued temporarily were receiving LPV/r;
they subsequently restarted and continued receiving TDF for the duration of the study.
Figure 1B shows the cumulative incidence over time of renal events resulting in
discontinuation of TDF. The difference between arms was not statistically significant
(p=0.14).
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Among all 741 women enrolled, there were 20 deaths, 5 of which were among patients with
renal events (5/24, 21%); 2 in the LPV/r arm and 3 in the NVP arm. For the 2 women
receiving LPV/r, the deaths occurred approximately 1 and 2 months (respectively) after the
onset of the renal event, and acute renal failure was the reported primary or contributing
cause of death in both patients. Among the 3 patients on the NVP arm with renal events who
died, 1 died approximately one week after the onset of the renal event with acute renal
failure as the reported primary cause; 1 died approximately 3 weeks after the onset of the
renal event with pulmonary embolus as the reported primary cause and the renal event was
ongoing; and 1 died approximately 6 months after onset and 5 months after the resolution of
the renal event from unknown causes (but had continued on study-provided antiretroviral
therapy after discontinuing TDF).
Logistic regression analysis was used to evaluate possible baseline (pre-treatment) factors
that might be associated with risk of development of a renal event (Table 2). Reflecting the
difference between randomized arms described above, there was a significantly higher odds
of a renal event in the LPV/r arm compared with the NVP arm (OR = 3.09, 95% confidence
interval [CI]: 1.21, 7.88; p=0.018). Additionally, in univariate analysis, several baseline
factors were associated with increased odds of developing a renal event: older age, higher
HIV-1 RNA, lower CrCl and lower CD4 count. However, when considering renal events
resulting in treatment change as the outcome, while randomized treatment was not
statistically significant (OR = 2.23 for LPV/r versus NVP, 95% CI: 0.77, 6.48; p=0.14),
older age, higher HIV-1 RNA, lower CrCl, lower CD4 count as well as lower hemoglobin
were significant (Table 2).
In multivariate analysis, we fitted a model which included randomized treatment, prior
exposure to single dose NVP, CrCl, HIV-1 RNA and age as covariates (Table 3; see
Methods for rationale for this model); other covariates considered in univariate analysis
were not significant when added to this model. In this model, LPV/r treatment arm was
significantly associated with having a renal event (OR = 3.12, 95% CI [1.21, 8.05], p =
0.019) as were higher baseline HIV-1 RNA and lower baseline CrCl (Table 3). However,
when considering renal events resulting in treatment modification as the outcome, higher
baseline HIV-1 RNA and lower baseline creatinine clearance were significantly associated
with increased odds of an event though there was a non-significant association with
treatment arm (p=0.16).
Discussion
In this large randomized clinical trial of HIV-infected women from resource limited settings
starting TDF-based cART regimens, 3% of women experienced renal events and 2%
required permanent treatment modification. The LPV/r treatment arm was associated with
increased overall renal events compared to the NVP treatment arm (4.9% vs. 1.6%) and
higher, though not statistically significant, rates of renal events leading to treatment
modification (3.0% vs. 1.4%). Additionally, higher baseline HIV RNA and lower baseline
CrCl were associated with both increased renal events and renal events leading to treatment
modification.
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The increased risk of renal events with LPV/r therapy and TDF co-administration is
plausible and consistent with previous research [7, 9, 10, 18]. TDF is eliminated by renal
clearance, with 20–30% of the filtered drug actively transported into renal proximal tubules.
From these proximal tubular cells, the drug is excreted by the multidrug resistance proteins
(MRPs). Ritonavir is a potent inhibitor of MRP-2[19–20]. Consequently, co-administration
of TDF with ritonavir could lead to accumulation of TDF within the proximal tubular cells
and possibly the development of TDF-associated renal proximal tubulopathy. Unfortunately,
we did not perform pharmacokinetic analysis of TDF levels in the study so we cannot
confirm if levels were increased in the LPV/r arm.
In one non-randomized study, greater declines in renal function have been observed among
patients treated with TDF and PI/r compared to TDF+NNRTI regimens [18]. Although the
degree of renal impairment found was relatively low, probably in part to a short period of
follow up (48 weeks), potential serious clinical implications for patients taking TDF co-
administered with LPV/r for longer durations were postulated. In our randomized study that
included a median 2.3 years of follow-up, while the LPV/r arm had more renal events over
time compared to the NVP arm, the events tended to occur earlier following treatment
initiation and the overall risk of serious renal toxicity due to TDF with long term use
remains low. However, as we did not measure glomerular filtration rate (GFR) for all
patients, subtle decreases in GFR may have been missed. Continued exposure to TDF even
in patients with subtle renal impairment may lead to progressive and significant renal
insufficiency [21]. Irreversible TDF-associated renal toxicity may be more likely among
those with a gradual decline in GFR as opposed to more acute renal damage [22]. In our
study, among those surviving their renal event there were no cases of chronic kidney
disease; this was likely due to close monitoring and cART modification, as mandated per the
protocol.
We found high baseline HIV-1 RNA and lower baseline CrCl to be associated with renal
insufficiency in multivariate analysis. Direct effects of HIV play an important role in the
development of HIV-associated nephropathy [23–24]. HIV-associated nephropathy has been
shown to be the most common cause of end stage renal disease in HIV patients, typically
occurring among patients with a relatively high viral burden and a CD4 count of < 200
cells/mm3 [25–26]. Indirectly, HIV proteins may mediate endothelial damage causing
platelet deposition within renal microvasculature through various mechanisms, leading to
HIV-induced thrombotic microangiopathy. This could explain the association in increasing
viral burden to the development of renal insufficiency we found in our analysis. In addition,
the low baseline CrCl is probably indicative of underlying renal disease even before
exposure to TDF. Others have also shown that baseline serum creatinine, age, CD4 count,
low hemoglobin, BMI, and CrCl are associated with decline in renal function among TDF-
treated patients [27–31].
Our study had several methodological limitations. The primary events, any renal event, and,
in particular, renal events leading to treatment change, consistent with previous studies
involving the use of TDF in resource limited settings [32–33], were uncommon (3%),
thereby limiting power to evaluate possible factors associated with risk. Also, we were not
able to evaluate factors associated with more subtle decreases in CrCl that remained above
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60mL/min but could represent significant declines compared to baseline. Urinalysis and
urine dipstick evaluation, as measure of tubular function, were not routinely collected,
thereby limiting interpretation of the renal events. In addition, our patient population was
exclusively female and so our results may not apply to males who generally have higher
body weights and muscle mass. In other settings, however, gender has not been associated
with development of renal insufficiency. We also did not explore the effect of other
concomitant medications or concurrent diseases that could potentially have caused of renal
insufficiency. However, despite these limitations, our study results are strengthened by the
fact that patients were randomized to the treatment groups and therefore had comparable
baseline characteristics and were managed by standardized toxicity protocols.
In most sub-saharan African settings, programs rely on public health approaches and renal
monitoring and determination of alternative etiologies of renal events are not readily
available or would require referral for specialist evaluation. Hence, the frequency of
laboratory monitoring of ART patients remains a relevant topic. The DART trial suggested
that toxicity monitoring did not improve overall outcomes among individuals receiving
either AZT/3TC/TDF or AZT/3TC/NVP [32] and renal events have been low in other
clinical trials using TDF in resource limited settings [31]. Based on these findings, many
countries using TDF-based therapy for first line therapy are not conducting routine renal
toxicity monitoring. However, the higher rates of renal events seen in our study among those
randomized to TDF combined with LPV/r may suggest monitoring in this population may be
beneficial. The timing of events in our study, occurring somewhat early in the treatment
course, may suggest a simplified toxicity algorithm could be applied to detect most cases.
Alternatively, policy makers may favor initial treatment of TDF with an NNRTI as first line
rather than using it as a component of second line when a boosted PI would be used.
Additionally, with expansion of use of LPV/r or TDF for prevention of mother-to-child-
transmission, further evaluation of renal function in this population is necessary.
In summary, the rate of renal events in the A5208 study was low, although women receiving
TDF co-administered with LPV/r had significantly more renal events both in magnitude and
over time, compared to those co-administering TDF with NVP. However, renal events did
not always require treatment modification, given our safety monitoring strategy. Finally,
high baseline HIV RNA and low baseline CrCl were factors associated with increased risk
of renal events, including those requiring treatment modifications.
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Table 1
Baseline characteristics of participants by randomized treatment arm
LPV/r NVP Total
Characteristic (N=371) (N=370) (N=741)
Age (years)
 Mean (SD) 33(7) 34(7) 34(7)
Height (cm)
 Mean (SD) 160(6) 159(6) 160(6)
Weight (kg)
 Mean (SD) 60(12) 60(13) 60(13)
BMI (kg/m2)
 Mean (SD) 24(5) 24(5) 24(5)
HIV-1 RNA (log10 copies/mL)
 Mean (SD) 5.0(0.7) 5.0(0.7) 5.0(0.7)
CD4 count (cells/mm3)
 Mean (SD) 124(73) 125(53) 124(64)
Hemoglobin (g/dL)
 Mean (SD) 11.6(1.8) 11.6(1.6) 11.6(1.7)
Serum creatinine (mg/dL)
 Mean (SD) 0.71(0.21) 0.70(0.15) 0.71(0.18)
Serum creatinine grade, number (%)±
 Normal 368(99.2) 368(99.5) 736(99.3)
 Mild (Grade 1) 1(0.3) 1(0.3) 2(0.3)
 Moderate (Grade 2) 0 0 0
 Severe (Grade 3) 2(0.5) 0 2(0.3)
 Potentially Life-threatening(Grade 4) 0 1(0.3) 1(0.1)
Creatinine Clearance (mL/min)
 Mean (SD) 112(34) 113(37) 112(35)
Single Dose NVP Exposure, number (%)
 Yes 121(32.6) 121(32.7) 242(32.7)
 No 250(67.3) 249(67.3) 499(67.3)
SD: standard deviation; BMI: body mass index; NVP: nevirapine; ULN: Upper Limit of Normal
±
Subjects with baseline grade 3 and 4 events were excluded from renal analysis. Grade 1 (1.1–1.3 X ULN), Grade 2(1.4–1.8 x ULN), Grade 3
(1.9–3.4 x ULN), Grade 4 (>=3.5 x ULN)
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